ISSN: 1474-4422

Journal Home

Journal Guideline

The Lancet Neurology Q1 Unclaimed

Lancet Publishing Group United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

The Lancet Neurology is a journal indexed in SJR in Neurology (clinical) with an H index of 315. It has an SJR impact factor of 11.674 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 11.674.

The Lancet Neurology focuses its scope in these topics and keywords: disease, disorders, brain, cohort, sporadic, traumatic, reality, multiple, patients, cerebral, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Neurology (clinical) (Q1)

Price

- €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

11.674

SJR Impact factor

315

H Index

267

Total Docs (Last Year)

792

Total Docs (3 years)

4508

Total Refs

11413

Total Cites (3 years)

290

Citable Docs (3 years)

15.9

Cites/Doc (2 years)

16.88

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Nature Reviews Neurology Q1
JAMA Neurology Q1
Acta Neuropathologica Q1
Alzheimer's and Dementia Q1
Brain Q1

Compare this journals

Aims and Scope

Best articles by citations

Neuromarketing: beyond branding

Chris Polman: quietly making multiple sclerosis research tick

Spinal-cord stimulation for reflex sympathetic dystrophy

Stroke 1-2-0: a rapid response programme for stroke in China

Molecular medicine for the brain: silencing of disease genes with RNA interference

Patients have their say on research priorities

Cytokines in sudden infant death syndrome

Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial

Acetylcholine and memory formation

Fall-out from a possible transfusion-related transmission of vCJD

Genetic testing and Huntington's disease: issues of employment

Clazosentan for patients with subarachnoid haemorrhage: lessons learned

SHOW MORE ARTICLES

Clazosentan for patients with subarachnoid haemorrhage: lessons learned -Authors' reply

Cost-benefit analysis for epilepsy surgery

Stroke in newborn infants

Has the real potential of cloning technology been overlooked?

AIDS and stroke risk

Rat studies of Ritalin emphasise need for proper ADHD diagnosis

New Indian centre to boost brain research and training

Media Watch

Friedreich's ataxia: treatment within reach

Yeast studies provide clues to neurodegeneration

EU to crack down on inequality of MS treatment